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Mechanisms of intrinsic resistance 
and acquired susceptibility of 
Pseudomonas aeruginosa isolated 
from cystic fibrosis patients to 
temocillin, a revived antibiotic
Hussein Chalhoub1, Daniel Pletzer2,†, Helge Weingart2, Yvonne Braun2, Michael M. Tunney3, 
J. Stuart Elborn3, Hector Rodriguez-Villalobos4, Patrick Plésiat5, Barbara C. Kahl6, 
Olivier Denis7, Mathias Winterhalter2, Paul M. Tulkens1 & Françoise Van Bambeke1
The β-lactam antibiotic temocillin (6-α-methoxy-ticarcillin) shows stability to most extended spectrum 
β-lactamases, but is considered inactive against Pseudomonas aeruginosa. Mutations in the MexAB-
OprM efflux system, naturally occurring in cystic fibrosis (CF) isolates, have been previously shown 
to reverse this intrinsic resistance. In the present study, we measured temocillin activity in a large 
collection (n = 333) of P. aeruginosa CF isolates. 29% of the isolates had MICs ≤ 16 mg/L (proposed 
clinical breakpoint for temocillin). Mutations were observed in mexA or mexB in isolates for which 
temocillin MIC was ≤512 mg/L (nucleotide insertions or deletions, premature termination, tandem 
repeat, nonstop, and missense mutations). A correlation was observed between temocillin MICs 
and efflux rate of N-phenyl-1-naphthylamine (MexAB-OprM fluorescent substrate) and extracellular 
exopolysaccharide abundance (contributing to a mucoid phenotype). OpdK or OpdF anion-specific 
porins expression decreased temocillin MIC by ~1 two-fold dilution only. Contrarily to the common 
assumption that temocillin is inactive on P. aeruginosa, we show here clinically-exploitable MICs on 
a non-negligible proportion of CF isolates, explained by a wide diversity of mutations in mexA and/
or mexB. In a broader context, this work contributes to increase our understanding of MexAB-OprM 
functionality and help delineating how antibiotics interact with MexA and MexB.
Pseudomonas aeruginosa is the most prevalent pathogen isolated in the respiratory tract of adult cystic fibrosis 
(CF) patients and a major cause of morbidity and mortality in this population1. These patients are frequently 
exposed to antipseudomonal antibiotics and, as a result, become colonized by multidrug-resistant strains. Since 
therapeutic choices narrow, clinicians are increasingly forced to look after “forgotten” antibiotics against which 
resistance rates could be low because they were scarcely used2.
Temocillin (6-α -methoxy-ticarcillin) is one of these old antibiotics recently revived, based on a renewed inter-
est for its activity against many β -lactam-resistant Enterobacteriaceae3. Temocillin, indeed, shows remarkable 
stability to most β -lactamases, including AmpC-type cephalosporinases and extended-spectrum β -lactamases 
(ESBLs) such as TEM, SHV, and CTX-M enzymes4. Temocillin also obtained an orphan drug designation for the 
treatment of Burkholderia cepacia complex infection in CF patients5. However, as temocillin was long considered 
1Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, 
Brussels, Belgium. 2Life Sciences, School of Engineering and Science, Jacobs University, Bremen, Germany. 3CF 
& Airways Microbiology Research Group, Queen’s University Belfast, Belfast, UK. 4Laboratoire de microbiologie, 
Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. 5Laboratoire de 
bactériologie, Hôpital Jean Minjoz, Besançon, France. 6University Hospital Münster, Münster, Germany. 7Laboratoire 
de microbiologie, Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium. †Present address: Centre for 
Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British 
Columbia, Vancouver, Canada. Correspondence and requests for materials should be addressed to F.V.B. (email: 
francoise.vanbambeke@uclouvain.be)
Received: 13 September 2016
Accepted: 01 December 2016
Published: 16 January 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:40208 | DOI: 10.1038/srep40208
Figure 1. Activity of temocillin and comparators against CF isolates of P. aeruginosa. Panel (a): Cumulative 
MIC distribution for temocillin (TMO) compared to ticarcillin (TIC), with indication of MIC50, MIC90 and 
percentage of susceptibility according to the interpretive criteria of EUCAST (S, susceptible; R, resistant) for 
ticarcillin (S ≤ 16 mg/L; R > 16 mg/L); piperacillin (PIP, S ≤ 16 mg/L; R > 16 mg/L); piperacillin-tazobactam 
(TZP, S ≤ 16 mg/L; R > 16 mg/L); ceftazidime (CAZ, S ≤ 8 mg/L; R > 8 mg/L); imipenem (IPM, S ≤ 4 mg/L; 
R > 8 mg/L); meropenem (MEM, S ≤ 2 mg/L; R > 8 mg/L). A value of 16 mg/L (dotted line in the graph; 
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as intrinsically inactive against P. aeruginosa, it was not included in conventional susceptibility testing of this 
organism when isolated from CF patients. Previous work from our laboratory actually showed that the intrinsic 
resistance of P. aeruginosa to temocillin was due to active efflux by the constitutively-expressed MexAB-OprM 
efflux transporter, while the other major efflux transporters were not involved6. Moreover, some isolates from 
CF patients regained susceptibility to temocillin because of natural mutations in the proteins constituting the 
MexAB-OprM efflux pump6. MexAB-OprM belongs to the Resistance Nodulation Division superfamily of efflux 
transporters. It is energized by proton motive force and consists of three proteins, namely an inner membrane 
exporter (homotrimer of MexB), an outer membrane gated channel (homotrimer of OprM), and a periplasmic 
linker (6 to 13-mer of MexA), the concerted action of which allows for the extrusion of substrates from the inner 
membrane or the periplasmic space directly out of the bacteria (ref. 7 for review). The role of porins in the capac-
ity of temocillin to cross the outer membrane is unknown so far. Among porins described in P. aeruginosa, the 
cation-selective channel OprD (OccD1) is involved in the entry of carbapenems (most notably, imipenem), while 
the anion-specific channels OpdK (OccK1) and OpdF (OccK2) are involved in the entry of carboxypenicillins 
like carbenicillin and of cefoxitin8.
In this context, the objective of this study was to better document the mechanisms of intrinsic resistance and 
acquired susceptibility to temocillin in P. aeruginosa isolated from CF patients. We exploited a large collection of 
333 isolates collected from 4 CF centres in Northern Europe, which has been partly characterized for its resistance 
to commonly used anti-pseudomonas agents9. We demonstrate that a non-negligible proportion of these isolates 
(~15–30%) showed low and clinically-exploitable MICs to temocillin, associated with a wide variety of mutations 
in mexA or mexB genes. No β -lactamase hydrolysing temocillin was found in the collection. A marginal role 
of anion-specific porins (OpdK and OpdF) in temocillin influx was also demonstrated. Besides its immediate 
interest for the management of infections in CF patients, this work also brings innovative pieces of information 
regarding mutations affecting the transport activity of the MexAB-OprM efflux system in P. aeruginosa, which 
can refine our understanding of the mechanism of substrate recognition and transport by this pump and may also 
help in reviving other antibiotics that are substrates of the same transporter.
Results
Activity of temocillin against clinical isolates and comparison with other β-lactams. Figure 1a 
shows the MIC distribution of temocillin compared to ticarcillin against the whole collection, with MIC50 and 
MIC90 of conventional antipseudomonal β -lactams illustrated in the accompanying Table. For temocillin, 15% 
and 29% of isolates had an MIC ≤ 8 and 16 mg/L, respectively. These values are close to those observed with 
ticarcillin (13% and 18%, respectively). Of interest, a similar proportion of isolates were susceptible to first-line 
antipseudomonal agents such as piperacillin, piperacillin/tazobactam, or ceftazidime. Carbapenems were active 
against a higher proportion of isolates.
Figure 1b–e shows cross-resistance between temocillin and the other β -lactams for individual isolates. While 
a high proportion of isolates were cross-resistant to temocillin and ticarcillin (64%), piperacillin/tazobactam 
(53%), ceftazidime (48%), or meropenem (40%), a small but meaningful proportion of isolates that were resistant 
to the comparator (ranging from 11% for meropenem to 18% for ticarcillin) remained susceptible to temocillin.
β-lactamases screening and identification. β -lactamase production is a main mechanism of β -lactam 
resistance in P. aeruginosa. We therefore screened the collection for extended spectrum β -lactamases (ESBLs) and 
carbapenemases. No carbapenemases were detected using both phenotypic and genotypic methods. Moreover, 
detection of genes encoding CTX-M, TEM, SHV, and BEL, PER, GES, VEB, or OXA β -lactamases returned neg-
ative results in all isolates that were simultaneously resistant to CAZ and MEM (MIC > 8 mg/L).
Influence of active efflux on temocillin activity. Previous studies suggested that active efflux by 
MexAB-OprM plays a major role in P. aeruginosa resistance to temocillin6. Using a representative subset of 
isolates (n = 124) selected to cover the whole range of MICs (8–14 isolates for each MIC value), we therefore 
examined the influence of the broad spectrum efflux pump inhibitor Phe-Arg-β -naphthylamide (PAβ N10) on 
temocillin activity. We checked that PAβ N was not toxic by itself for these isolates in the conditions of the exper-
iment. MICs were shifted towards lower values in the presence of the inhibitor (Fig. 2a), with its effect being par-
ticularly marked for isolates showing MICs ranging between 128 and 512 mg/L in the absence of PAβ N (Fig. 2b). 
To confirm the role of MexAB-OprM-mediated efflux in resistance to temocillin, we followed in real-time the 
efflux of N-phenyl-1-naphthylamine (NPN), a preferential MexAB-OprM substrate11, using temocillin as a com-
petitor and comparing PAO1 to its MexAB-OprM deletion mutant PAO1mexAB (Fig. 2c). NPN efflux was much 
slower in the deletion mutant than in the parent strain. Temocillin was able to decrease the rate of efflux of NPN 
in PAO1 but had no effect in the MexAB-OprM deletion mutant even when using a temocillin concentration 
EUCAST susceptibility breakpoint of ticarcillin) has been considered as cut-off value for temocillin (TMO), for 
comparison purposes. Panels (b–e): cross-resistance between TMO and other β -lactams. Correlation between 
MICs of TMO (abscissa) and TIC, CAZ, TZP or MEM (ordinate) for each individual isolate in the collection 
using quantile density contour analysis (JMP® version 12.1.0). The intensity of each zone (from warm to 
cold colours) is indicative of the proportion of isolates (from large to small) with MICs at the corresponding 
coordinates. The broken lines point to the MIC value above which the isolates are considered resistant for TIC, 
CAZ, TZP and intermediate for MEM according to EUCAST interpretive criteria. A value of 16 mg/L has been 
considered for TMO. The percentage of isolates is indicated in each quadrant of the figures. MICs values are 
expressed as the log2 of their value.
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Figure 2. Influence of active efflux on temocillin activity. (a) Cumulative MIC distribution of temocillin 
in a subset of the collection (n = 124) selected to cover the whole range of MICs and influence of the efflux 
pump inhibitor PAβ N (20 mg/L). (b) Fold reduction (log2 scale) in temocillin MIC in the presence of PAβN, 
according to temocillin MICs for the same isolates. The graph shows the box and whiskers plot with 10-90 
percentiles, with the red line connecting the medians. (c) Kinetics of NPN efflux from PAO1 or PAO1mexAB 
in the absence (control) or presence of temocillin (TMO) at the indicated concentrations. Vmax are expressed 
www.nature.com/scientificreports/
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much higher than its MIC (2 mg/L). These data strongly suggest that temocillin is a preferential substrate of 
MexAB-OprM. The rate of efflux of NPN was therefore evaluated in 32 isolates (29 clinical isolates plus PAO1, 
PT629, PAO1mexAB) harbouring increasing temocillin MICs (Fig. 2d). NPN efflux was significantly slower for 
isolates with a temocillin MIC < 512 mg/L and increased in proportion to temocillin MIC.
Mutations in mexA and mexB in relation with temocillin MIC and efflux pump activity. MexA 
and MexB, but not OprM, determine the β -lactam specificity of the MexAB-OprM efflux system12. We therefore 
sequenced mexA and mexB genes in the 32 isolates for which NPN efflux was evaluated. Figure 2e,f illustrates 
the relationship between the type of mutations evidenced and the MIC of temocillin or the rate of efflux of NPN. 
Isolates harboring deletions in mexA or mexB or aberrant sequences (deletion of ≥ 3 consecutive nucleotides, 
nonsense mutation, nonstop mutation13, aberrant signal peptide, minisatellite repeat) had the slowest rate of 
efflux of NPN and temocillin MICs ranging between 2 and 128 mg/L. Isolates with missense mutations globally 
showed a slower efflux than PAO1 and temocillin MICs of 128 or 256 mg/L. Synonymous mutations did not 
impact NPN efflux or temocillin MICs. In addition, most of the isolates showed a high frequency of synonymous 
mutations and codon degeneracy especially at the third position. Most of them were conserved between different 
isolates originating from different countries.
Table 1 summarizes these results and shows in parallel for each isolate the Vmax for NPN efflux, together with 
(i) the MICs of temocillin in control conditions or in the presence of the efflux pump inhibitor PAβ N or of the 
OpdK porin substrate vanillate, and (ii) the relative amount of exopolysaccharides. The constructed molecular 
graphics of the corresponding proteins are illustrated in Table S2 (see also Fig. S1 for a view of the wild-type pro-
teins, with specification of their subdomains).
Tables S2b–e specifically focus on sequenced isogenic isolates collected either from the same patient or from 
different patients originating either from the same or from different countries. Table S2b illustrates isolates col-
lected in the UK and belonging to the Liverpool epidemic strain (LES)9. Isolates from five different patients 
with an MIC of 16 mg/L shared the same synonymous mutations and also the same nonsense mutation in mexA 
leading to the production of a 119 amino acid protein. Of note, two other LES isolates with an MIC of 32 mg/L 
shared the same synonymous mutations in mexA and mexB genes as those described for the first 5 LES isolates, 
but harboured different deletions in their mexB gene, leading to proteins of 30 and 672 amino acids, respectively. 
Table S2c illustrates 2 pairs of isolates harbouring the same mutations although collected from different patients 
in the same country. Thus, in the isogenic isolates 191-4 and 2079 with a temocillin MIC of 64 mg/L, MexA 
was truncated to 27 amino acids. Likewise, in isogenic isolates W024 and W049 with a MIC of 4 mg/L, MexA 
was truncated to 69 residues due to the loss of 1 nucleotide leading to a premature stop codon. Interestingly 
also, isogenic isolates can be found in different countries (Table S2d). These three isolates belonging to the same 
multidrug-resistant clonal complex9 and originating from the UK (AG3), Belgium (128) and Germany (129-6) 
shared the same synonymous mutations. Only AG3 had a low MIC to temocillin (8 mg/L), associated with a 
MexA protein truncated in its MP domain (372 amino acids left). The two other isolates had MICs of 1024 mg/L, 
with one conservative missense mutation (L376V) found in the transmembrane domain TM3 of the MexB pro-
tein of isolate 128. Finally, Table S2e illustrates three other clonal isolates differing in their susceptibility to temo-
cillin. They come from two different patients in Germany and share (i) a radical missense mutation (G616T) in 
the mexA part encoding the third domain of MexA interacting with the distal domain of MexB, (ii) a conservative 
missense mutation (A556G), and (iii) a deletion of nucleotides 1947 and 1948 in mexB. In addition, isolate 135-1, 
with a temocillin MIC of 8 mg/L, showed an insertion in mexB (G1261_C1262insG) leading to the production of 
an aberrant and truncated MexB protein. In contrast, isolates 208-3 and 208-2, with temocilllin MIC of 256 and 
512 mg/L, differed only by the position of an additional 1 nucleotide deletion (in position 1854 or 1889, respec-
tively) in the mexB gene part encoding the pore (PC1) subdomain, leading to the replacement of 30 by 29 amino 
acids, and of 19 by 18 amino acids, respectively. This difference could explain the 1 two-fold dilution difference in 
temocillin MIC between these two isolates.
Despite the evidenced truncations or mutations in MexA and MexB, most of the clinical isolates showed 
nevertheless higher temocillin MICs than the reference strain PAO1mexAB lacking MexA and MexB proteins 
(see Fig. 2e). This strongly suggests that other mechanisms of resistance independent of the functionality of 
MexAB-OprM are present.
Culture content in extracellular polymeric saccharides with β-1, 4 and β-1, 3 linkages. P. aerug-
inosa isolated from CF patients often harbour a mucoid phenotype, related to the overproduction of extracellular 
polysaccharides, among which alginate contributes to the chronicity of infections. Alginate production has been 
shown to impede the activity of β -lactams, including ticarcillin14,15.
in reduction in the fluorescence signal per second. (d) Kinetics of efflux of NPN as a function of temocillin 
MIC for the 32 isolates for which mexA and mexB were sequenced (Table 1). The ordinate is expressed as the 
Vmax (arbitrary fluorescence units). R2 for a one-phase association: 0.9043. Node splitting value for slower 
efflux: MIC  of 256 mg/L or lower (LogWorth statistic: 29.5157 [p < 0.001]). (e,f) MIC and rate of NPN efflux 
in sequenced isolates classified according to the type of mutations observed in mexA and mexB (Table 1). 
‘Truncated/aberrant’ refer to deletions of more than 3 consecutive nucleotides in the sequence, nonstop 
mutations, insertion of minisatellites or aberrant signal peptides. ‘Missense mutations’ refer to mutations 
leading to the replacement of at least one amino acid in the corresponding protein. The graphs shows individual 
values together with means and SD. Statistical analysis (1-way ANOVA; Tuckey post-hoc test): data series with 
different letters are different from one another (p < 0.05).
www.nature.com/scientificreports/
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Reference strains 
and clinical isolates 
(patient’s identification 
code; country; date of 
collection)
Description (phenotype; 
length of MexA/B protein; 
AA deletions and affected 
MexA/B domains)
Efflux characteristics MIC (mg/L)
EPS (β-1, 
4/β-1, 3 
glycosidic 
bonds)mexA alterations mexB alterations
Vmax 
(units/s) TMO
TMO 
+PAβN TMO+VNL
PAO1 Wild type MexA (383 AA) MexB (1046 AA) — — − 0.480 512 128 768 1
PT629a PAO1 MexAB-OprM overproducer — — − 0.720 1024 256 1536
PAO1mexABa PAO1 ΔmexAB — — − 0.112 2 2 2
3724 (AL1; France; 
14/12/2006)
-MexA (383 AA).
-Truncated MexB (878 AA): 
S879_Q1046del deletion 
of 168 AA affecting 5 TMs 
(TM8-TM12).
-Uncommonb 
synonymous mutations: 
C546G 
-Prevalentb synonymous 
mutations: A345G 
G993A
-Uncommon synonymous mutations: 
C486T 
-Prevalent synonymous mutations: 
A495G C1308T C1692T T2280C 
T2730C G3117A
-Nonsense mutation: C2636A 
− 0.178 2 2 4 1.2
144 (PCF79; Belgium; 
20/09/2010)
-Truncated MexA (124 AA): 
A125_G383del deletion 
of 259 AA affecting the α 
-hairpin, second, third and 
MP domains. 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: G993A
-Nonsense mutation, 
Δ 13 nt (367–379)
Prevalent synonymous mutations: 
A495G T2280C T2730C G3117A − 0.016 2 2 4 1.1
W024 (DM; UK; 2009)
-Truncated MexA (69 AA): 
V70_G383del deletion of 
314 AA in α -hairpin, second, 
third and MP domains.
-MexB (1046 AA)
Nonsense mutation, Δ 
1 nt (164) No mutations − 0.117 4 2 6 1.4
W049 (DB; UK; 2009)
-Isogenic to W024
-Truncated MexA (69 AA): 
V70_G383del deletion of 
314 AA in α -hairpin, second, 
third and MP domains.
-MexB (1046 AA)
Nonsense mutation: 
Δ1 nt (164) No mutations − 0.117 4 2 6 2.2
143-1 (143; Germany; 
12/07/2012)
-Nonstop mutation in 
mexA (stalled ribosome, 
proteolysis; recycled 
ribosome)13
-MexB (1046AA)
-Prevalent synonymous 
mutation: G993A
-Nonstop mutation: Δ 
2 nt (837–838)
-Uncommon synonymous mutations: 
C2412T 
-Prevalent synonymous 
mutations:A495G T2226C T2280C 
T2730C G3117A
− 0.019 4 4 8 0.5
AG3 (JP; UK; 
10/05/2006)
-Shortened MexA (372 AA): 
G337_E347del deletion of 11 
AA in the MP domain.
-MexB (1046AA) 
-Prevalent synonymous 
mutations: A345G 
G993A
-Deletion: Δ 33 nt 
(1011–1043)
Prevalent synonymous mutations: 
C474T C492T A495G T2280C 
T2730C G3117A
− 0.004 8 4 12 1.4
129 (RCF62; Belgium; 
09/09/2010)
-MexA (383 AA).
-MexB (1045 AA): N254del 
deletion of asparagine 254 
in the DN subdomain and 
missense mutation (T557N) 
in TM7.
-Uncommon 
synonymous mutations: 
C633T G702A C780T
-Prevalent synonymous 
mutations: T333C 
A345G G447A A639G 
T655C T729C C732T 
A738G C789G G792A 
T1002C T1095C 
-Uncommon synonymous mutations: 
C909T G1362A 
-Prevalent synonymous mutations: 
A495G T2730C G3117A
-Conservative missense mutation: 
C1670A
-Deletion: Δ3 nt (760–762)
− 0.053 8 2 12 1.1
135-1 (135; Germany; 
10/07/2012)
-MexA (383 AA): A206S 
missense mutation (third 
domain).
-MexB truncated (719 AA): 
M720_Q1046del deletion 
of 327 AA in DC, PN1, PC2 
and TM8-TM12 and 300 
AA substitutions (I186V; 
M421_719) in TM5-7, DN, 
PC1, and PC2.
-Uncommon 
synonymous mutations: 
G438T G558C 
-Prevalent synonymous 
mutations: T333C 
A345G G447A A639G 
T655C T729C C732T 
A738G C789G G792A 
C951G T1002C T1095C 
-Radical missense 
mutation: G616T
-Uncommon synonymous mutations: 
G348A C1101T C1389A
-Prevalent synonymous mutations: 
C315T A351G A495G C498G G591A 
C600G C537T A1938G T2067C 
A2079G T2280C T2730C
-Conservative missense mutation: 
A556G
-Insertion and deletion leading 
to premature stop codon: G1261_
C1262insG + Δ 2 nt (1947–1948)
− 0.100 8 8 12 3.8
126 (VIF68; Belgium; 
09/09/2010)
-SCV isolate.
-MexA (383 AA): aberrant 
signal peptide (S19L).
-MexB (1046 AA): missense 
mutations (I186V, Q773P) in 
DN and DC subdomains at 
the OprM-docking domain 
of MexB 
-Uncommon 
synonymous mutations: 
C582T C912T
-Prevalent synonymous 
mutations: T333C 
A345G G447A T655C 
T729C C789G G792A 
C951G T1002C T1095C
-Radical missense 
mutation: C56T 
-Uncommon synonymous 
mutations:C1314A G2004A C2014T 
-Prevalent synonymous mutations: 
C315T A351G A495G C498G C537T 
G591A C600G A804C G1587T 
T1749C A1938G T2067C A2079G 
T2226C T2280C T2730C T2826C 
A2892G C2955T
-Conservative missense mutation: 
A556G
-Radical missense mutation: A2318C
− 0.007 8 2 12 3.3
279 (RRM59; Belgium; 
28/10/2010)
-MexA (383 AA). 
-Aberrant MexB (1027 AA): 
K151_T169del deletion of 19 
amino acids in the periplasmic 
pore domain (subdomain 
PN2)
No mutations
-Prevalent synonymous mutations: 
A351G C1308T T2280C T2730C 
G3117A
-Deletions: Δ57 nt (455–511)
− 0.016 16 4 24 2
Continued
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Reference strains 
and clinical isolates 
(patient’s identification 
code; country; date of 
collection)
Description (phenotype; 
length of MexA/B protein; 
AA deletions and affected 
MexA/B domains)
Efflux characteristics MIC (mg/L)
EPS (β-1, 
4/β-1, 3 
glycosidic 
bonds)mexA alterations mexB alterations
Vmax 
(units/s) TMO
TMO 
+PAβN TMO+VNL
BM1 (AD; UK; 
13/09/2006)
- LES isolate.
-Truncated MexA (119 AA): 
Y120_G383del deletion of 
264 AA in α -hairpin, second, 
third and MP domains. 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
C360G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
− 0.025 16 16 16 3.7
AJ3 (ML; UK; 
22/05/2006)
- LES isolate.
-Truncated MexA (119 AA): 
Y120_G383del deletion of 
264 AA in α -hairpin, second, 
third and MP domains. 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
C360G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
− 0.025 16 16 32 1.4
CF15 (CT; UK; 2007)
-LES isolate. 
-Truncated MexA (119AA): 
Y120_G383del deletion of 
264 AA in α -hairpin, second, 
third and MP domains. 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
C360G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
− 0.025 16 16 24 3.2
CF53 (DP; UK; 2007)
-LES isolate.
-Truncated MexA (119 AA): 
Y120_G383del deletion of 
264 AA in α -hairpin, second, 
third and MP domains). 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
C360G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
− 0.025 16 16 32 1.6
CF19 (LS; UK; 2007)
-LES isolate. 
-Truncated MexA (119 AA): 
Y120_G383del deletion of 
264 AA in α -hairpin, second, 
third and MP domains). 
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
C360G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
− 0.025 16 16 24 1.9
CF16 (RC; UK; 2007)
-LES isolate. 
-MexA (383 AA). 
-Truncated MexB (30 AA): 
P31_Q1046del only TM1 is 
encoded.
Prevalent synonymous 
mutation: A345G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
-Nonsense mutation: Δ 154 nt 
(85–239)
− 0.120 32 8 48 2.7
BV1 (DC; UK; 
11/10/2006)
-LES isolate.
-MexA (383 AA).
-Truncated MexB (672 AA): 
E673_Q1046del deletion 
of 374 AA in DC, PN1, PC2 
and TM8-TM12, and 154 AA 
substitutions (F519_G672) in 
TM6-7, PC1 subdomains.
Prevalent synonymous 
mutation: A345G
-Uncommon synonymous mutation: 
T2015G 
-Prevalent synonymous mutations: 
A495G, C1692T, T2280C, T2730C, 
G3117A
-Nonsense mutation: Δ 8 nt 
(1555–1562)
− 0.080 32 8 64 3.6
191-4 (191; Germany; 
03/09/2012)
-Truncated MexA (27 AA): 
E28_G383del deletion of 
356 AA.
-MexB (1046 AA).
-Prevalent synonymous 
mutation: G993A 
-Nonsense mutation: 
G82T
Prevalent synonymous mutations: 
A495G T2280C T2730C G3117A − 0.014 64 32 128 4.1
207 (207; Germany; 
2012)
-Truncated MexA (27 AA): 
E28_G383del deletion of 
356 AA.
-MexB (1046 AA).
-Prevalent synonymous 
mutation: G993A 
-Nonsense mutation: 
G82T
Prevalent synonymous mutations: 
A495G T2280C T2730C G3117A − 0.014 64 32 64 2.6
109 (ENM88; Belgium; 
03/09/2010)
-MexA (383 AA).
-15 base pairs (5 AA 
residues PAIAP [P36_P40]) 
minisatellite repeat in 
MexB (1051 AA), toxic or 
malfunctioning proteins. 
-Uncommon 
synonymous mutation: 
G117A C468T
-Prevalent synonymous 
mutations: T333C 
A345G G447A T729C 
T1002C
-Uncommon synonymous mutations: 
G1452A C1920T 
-Prevalent synonymous mutations: 
C315T A351G A495G T642C A804C 
C1308T T1749C A1938G T2067C 
A2079G T2226C T2280C
-15 nt minisatellite repeat: 118–132c
− 0.008 64 toxic 64 2.5
618 (FJ1; France; 
01/01/1996)
-Truncated MexA (297 AA): 
V298_G383del, deletion of 86 
AA in MP domain.
-MexB (1046 AA)
-Prevalent synonymous 
mutation: A345G
-Nonsense mutation: 
Δ1 nt (C869)
Prevalent synonymous mutations: 
A495G C1308T C1851T T2067C 
T2226C T2280C T2730C T2826C 
A2892G C2955T G3117A
− 0.114 128 toxic 128 2.9
3179 (MP1; France; 
03/02/2004)
-SCV isolate.
-MexA (383 AA).
-Truncated MexB (719 AA): 
M720_Q1046del deletion of 
327 AA in TM8-TM12, DC 
and PN1/PC2 subdomains.
Prevalent synonymous 
mutation: G993A
-Prevalent synonymous mutations: 
A495G C1308T C1851T T2067C 
T2226C T2280C T2730C T2826C 
A2892G C2955T G3117A
-Nonsense mutation: Δ1 nt (G2147)
− 0.117 128 128 192 3.1
180-3 (180; Germany; 
30/07/2012)
-MexA (383 AA): W332R 
missense mutation in MP 
domain; 
-MexB (1046 AA)
-Prevalent synonymous 
mutations: A345G 
T729C T1002C
-Radical missense 
mutation: T994C
-Uncommon synonymous mutation: 
G1608A 
-Prevalent synonymous mutations: 
C492T A495G T2280C T2730C 
G3117A
− 0.185 128 32 128 1.2
Continued
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We therefore compared exopolysaccharide abundance in cultures of 73 clinical isolates (included those which 
had been sequenced) vs. PAO1 by measuring calcofluor white binding to polysaccharides (Fig. 3). A high varia-
bility in fluorescence values was observed among isolates, but a global statistical analysis showed that the increase 
in fluorescence signal was significant for isolates with a temocillin MIC ≥ 4 mg/L. Notably, among sequenced iso-
lates with truncated or aberrant MexA or MexB, the fluorescence signal was at least 2.6-fold higher than in PAO1 
for those for which temocillin MICs are between 32 to 128 mg/L.
Reference strains 
and clinical isolates 
(patient’s identification 
code; country; date of 
collection)
Description (phenotype; 
length of MexA/B protein; 
AA deletions and affected 
MexA/B domains)
Efflux characteristics MIC (mg/L)
EPS (β-1, 
4/β-1, 3 
glycosidic 
bonds)mexA alterations mexB alterations
Vmax 
(units/s) TMO
TMO 
+PAβN TMO+VNL
3319 (BV1; France; 
03/08/2004)
-MexA (383 AA); 
-MexB (1046 AA): Y182C, 
A707S, I963V, S1041E and 
V1042A, missense mutations 
in PC2, DN, TM11, and 
cytoplasmic C-terminal 
domain.
-Uncommon 
synonymous mutations: 
G51T C147G C291T 
G399A C423T G426A 
C591T C651T C687T 
C705T C777A
-Prevalent synonymous 
mutations: T333C 
A345G G447A T655C 
T729C C951G T1002C
-Uncommon synonymous mutations: 
C129T G165A T423G T519C G1080A 
C1152T T1332C C1383T C1476G 
T1563C C1581T C1614T A1713G 
G1748C T1758G G1836C C1980T 
G2001T C2070A C2134T A2139G 
C2148T C2223T G2319A T2457C 
G2469C C2604A T2907C T3033C
-Prevalent synonymous mutations: 
A351G A495G C498G C537T T642C 
A804C G1587T T1749C T2067C 
T2226C T2280C T2730C A2892G 
C2955T 
-Radical missense mutation: G2119T
-Conservative missense mutations: 
A545G; A2887G; G3120T T3121G 
C3122A C3123G T3125C
− 0.150 256 32 384 1.8
208-3 (208; Germany; 
09/08/12)
-Isogenic to 135-1.
-MexA (383 AA): missense 
mutation A206S (third 
domain).
-MexB (1045 AA): 
missense mutation I186V 
(DN subdomain), and 30 
AA replaced by 29 new 
AA (R620_R650 in PC1 
subdomain).
-Uncommon 
synonymous mutations: 
G438T G558C 
-Prevalent synonymous 
mutations: T333C 
A345G G447A A639G 
T655C T729C C732T 
A738G C789G G792A 
C951G T1002C T1095C 
-Radical missense 
mutation: G616T 
-Uncommon synonymous mutations: 
G348A C1101T
-Prevalent synonymous mutations: 
C315T A351G A495G C498G C537T 
G591A C600G A1938G T2067C 
A2079G T2280C T2730C
-Conservative missense mutation: 
A556G
-Deletions: Δ 1 nt (T1854) + Δ 2 nt 
(1947–1948)
− 0.320 256 256 256 4.4
208-2 (208; Germany; 
09/08/12)
-Isogenic to 135-1. 
-MexA (383 AA): missense 
mutation A206S (third 
domain). 
-MexB (1045 AA): 
missense mutation I186V 
(DN subdomain), and 19 
AA replaced by 18 new 
AA (L631_R650 in PC1 
subdomain)
-Uncommon 
synonymous mutations: 
G438T G558C 
-Prevalent synonymous 
mutations: T333C 
A345G G447A A639G 
T655C T729C C732T 
A738G C789G G792A 
C951G T1002C T1095C 
-Radical missense 
mutation: G616T
-Uncommon synonymous mutations: 
G348A C1101T
-Prevalent synonymous mutations: 
C315T A351G A495G C498G C537T 
G591A C600G A1938G T2067C 
A2079G T2280C T2730C
-Conservative missense mutation: 
A556G
-Deletions: Δ 1 nt (T1889) + Δ 2 nt 
(1947–1948)
− 0.253 512 256 512 4.6
128 (DAF69; Belgium; 
09/10/2010)
-Isogenic to AG3.
-MexA (383 AA).
-MexB (1046 AA): L376V, 
missense mutation in TM3.
Prevalent synonymous 
mutations: A345G 
G993A
-Prevalent synonymous mutations: 
C474T C492T A495G T2280C 
T2730C G3117A 
-Conservative missense mutation: 
C1126G 
− 0.576 1024 1024 1024 4.9
129-6 (129; Germany; 
11/07/2012)
-Isogenic to AG3.
-Synonymous mutations in 
MexA (383 AA) and MexB 
(1046 AA) 
Prevalent synonymous 
mutations: A345G 
G993A
Prevalent synonymous mutations: 
C474T C492T A495G T2280C 
T2730C G3117A
− 0.672 1024 256 1536 2.1
4289 (JV1; France; 
13/08/2007)
-Synonymous mutations in 
MexA (383 AA) and MexB 
(1046 AA)
Prevalent synonymous 
mutations: G993A
Prevalent synonymous mutations: 
A495G T2280C T2730C G3117A − 0.528 1024 512 1536 1.5
Table 1.  Efflux characteristics, MIC and relative polysaccharide content for reference strains versus CF 
clinical isolates of P. aeruginosa. aSee ref. 6 for references. bUncommon synonymous mutations: rare mutations 
found in isolates belonging to only one clone or one single patient; prevalent synonymous mutations: identical 
mutations found in different isolates belonging to different clones. cThe presence of minisatellites could be 
consecutive to bacterial exposure to genotoxic compounds42,43; the resulting proteins are malfunctioning. The 
table shows (a) the mutations detected in mexA and mexB and the changes in the corresponding proteins, the 
Vmax for NPN efflux (see Fig. 2, panels c-d), (b) temocillin MICs in control conditions, or in the presence 
of 20 mg/L PAβ N as efflux pump inhibitor and 2 mM vanillate (VNL) as OpdK substrate, and (c) the culture 
content in exopolysaccharides relative to PAO1 (see Fig. 3). Abbreviations used: TM, transmembrane α -helix; 
MP, membrane-proximal domain; PN1/PN2 (periplasmic, N-terminal), PC1/PC2 (periplasmic, C-terminal), 
DN (docking, N-terminal) and DC (docking, C-terminal) are six periplasmic subdomains that build the pore 
and docking domains of MexB, respectively (see Fig. S1 for more details); nt, nucleotide; AA, amino acids; SCV, 
small colony variant; LES, Liverpool Epidemic Strain; EPS, extracellular polymeric saccharides. Molecular 
graphics for mexA and mexB mutants are represented in the supplementary data (Table S2a–e) together with the 
position of the different protein domains.
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Influence of porins on temocillin activity. β -lactams are known to cross the outer membrane of 
Gram-negative bacteria via porins.
While OprD (OccD1) has been well characterized as facilitating the entry of carbapenems (mainly imipenem16) 
into P. aeruginosa, other members of the OprD family like OpdK (OccK1, archetype of the OccK subfamily17) 
and OpdF (OccK2) are involved in the transport of the carboxypenicillin carbenicillin and of the anionic cepha-
losporin cefoxitin8. As temocillin is also a carboxypenicillin, we examined whether these anion-selective porins 
were involved in temocillin transport into P. aeruginosa. OprD was studied in parallel. Other members of the 
OprD family of porins were not investigated in the present work.
MICs of temocillin, cefoxitin, imipenem, and meropenem were measured in transformants of a porin-deficient 
E. coli strain expressing OpdK, OpdF, or OprD (Table 2; carbenicillin could not be tested due to the presence of 
a β -lactamase-encoding gene on the transforming plasmid). Consistent with previous studies8, OprD expression 
increased the activity of carbapenems but not that of the other drugs. Conversely, the expression of OpdK, and to 
a slightly lesser extent, of OpdF, increased the activity of temocillin and cefoxitin; this effect was best seen when 
the antibiotics were combined with PAβ N.
Figure 3. Evaluation of exopolysaccharide abundance in cultures of clinical isolates as compared to the 
reference strain PAO1 as a function of temocillin MICs. Calcofluor white (CFW) fluorescence was measured 
for 73 clinical isolates, including those for which mexA and mexB were sequenced (Table 1). Data expressed as a 
ratio to the value measured for the non-mucoid reference strain PAO1 (highlighted by the dotted line), the MIC 
of which is 512 mg/L). The red horizontal lines show the mean of values for 7–8 isolates for each MIC (3 only for 
32 mg/L [no more isolates with this MIC value in the whole collection]). Statistical analysis: figures above each 
bar represents the p value (multiple t-test) versus PAO1. Node splitting value for significant increase in CFW 
fluorescence signal vs. PAO1: MIC = 4 mg/L or higher LogWorth statistic: 1.6343 [p 0.02].
Strains
Antibiotic MIC (mg/L)a
TMO FOX
IPM MEMcontrol +PAβNb control +PAβNb
W3110 Δ ompF/C + pBAD-Empty 40 18 80 20 1 1.5
W3110 Δ ompF/C + pBAD-oprD 40 18 80 20 0.225 0.225
W3110 Δ ompF/C + pG-Empty 40 18 80 20 1 1.5
W3110 Δ ompF/C + pG-opdK clone 1c 20 9 56 16 1 1.5
W3110 Δ ompF/C + pG-opdK clone 2c 20 9 56 16 1 1.5
W3110 Δ ompF/C + pG-opdF clone 1c 22 14 60 18 1 1.5
W3110 Δ ompF/C + pG-opdF clone 2c 22 14 60 18 1 1.5
Table 2.  Influence of porins on antibiotic activity in E. coli transformants expressing oprD/Occd1, opdK/
occK1, or opdF/occK2. aMICs (mg/L) of temocillin (TMO), cefoxitin (FOX), imipenem (IPM), and meropenem 
(MEM) were determined in the presence of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 0.5 mM or 
arabinose 0.5% as gene inducers. Values in bold highlight increased activity vs. the corresponding control (no 
porin expressed). b20 mg/L PAβ N added as an inhibitor of E.coli AcrAB-TolC efflux pump.
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Subsequently, MICs were measured in P. aeruginosa mutants of each of these three porins (Table 3). MICs for 
carbapenems were markedly (3–4 log2 dilutions) increased by the loss of OprD while those of temocillin and car-
benicillin were not affected. Conversely, deletion of OpdK or OpdF modestly (< 1 log2 dilution) increased the MIC 
of carboxypenicillins. This effect was amplified in the presence of vanillate (substrate for OpdK17,18) in the OpdF 
mutant for carboxypenicillins, suggesting that these two porins cooperate for the import of these antibiotics. 
Likewise, L-Arginine (substrate for OprD19) reduced carbapenem activity in the OpdK or OpdF mutants. The 
effect of vanillate on temocillin activity against clinical isolates is illustrated in Fig. 4a (MIC distribution) and in 
Table 1 (individual isolates). This effect was modest, but best seen in isolates with temocillin MICs ≤ 64 mg/L, in 
which efflux was deficient (Fig. 4b).
Discussion
This study is the first to describe the activity of temocillin in a large collection of P. aeruginosa collected from 
CF patients, and to determine the mechanisms that can lead to a phenotype of ‘acquired susceptibility’ to this 
antibiotic, which is uncommon in this pathogen3. Our results showed that a low but significant proportion of the 
isolates have MICs lower than the current temocillin BSAC (British Society for Antimicrobial Chemotherapy) 
susceptibility breakpoint for systemic infections, and to the current EUCAST breakpoint for the parent molecule 
ticarcillin, as well as to the breakpoint proposed for high dosing regimens of temocillin based on pharmacoki-
netic/pharmaocodynamic considerations20. Even if far from being the majority, these susceptible isolates cannot 
be ignored, as 30 to 60% of them are resistant to conventional antipseudomonal β -lactams, including carbapen-
ems, making temocillin one of the last viable therapeutic option.
We confirm that altered active efflux mediated by MexAB-OprM is the main driver of restored susceptibility 
to temocillin. Non-functional efflux, as evidenced using NPN as a tracer, was observed in isolates with temocillin 
Strain
Antibiotic MIC (mg/L)a
TMO CAR MEM IPM
control + VNL + L-Arg control + VNL + L-Arg control + VNL + L-Arg control + VNL + L-Arg
PA14 256 384 256 48 64 48 0.37 0.37 1 1 1 2
PA14::oprD 256 384 256 48 64 48 3 3 3 4 4 4
PA14::opdKb 384 384 384 64 64 64 0.37 0.37 1 1 1 2
PA14::opdFb 384 786 384 64 128 64 0.37 0.37 1 1 1 2
Table 3. Influence of porins on antibiotic activity in P. aeruginosa PA14 and its single disruptants for the 
oprD, opdK, or opdF genes. aMICs (mg/L) of temocillin (TMO), carbenicillin (CAR), imipenem (IPM), and 
meropenem (MEM) were determined in the presence of 2 mM vanillate (VNL) or 10 mM L-Arg as competitor 
substrates for OpdK and OprD, respectively. Values in bold highlight decreased activity vs. the corresponding 
control (no porin substrate added); values in italics highlight decreased activity vs the wild-type strain PA14. 
bTwo different clones transformed with pG-OpdK or pG-OpdF tested.
Figure 4. Influence of porins on temocillin activity. (a) Cumulative MIC distribution of temocillin in a subset 
of the collection (n = 31) selected to cover the whole range of MICs and influence of the OpdK competitor 
vanillate (VNL 2 mM). (b) Fold reduction (log2 scale) in temocillin MIC in the presence of VNL, according to 
temocillin MICs for the same isolates. The graph shows the box and whiskers plot with 10–90 percentiles, with 
the red line connecting the medians.
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MICs < 512 mg/L, and these also harbour mutations in mexA and/or mexB leading to protein alterations. Among 
the sequenced isolates, we could evidence a whole panel of mutations that may lead to loss of functionality, many 
of which had not been reported in our earlier study of temocillin-susceptible CF isolates6, neither in other studies 
investigating the effect of mexA/B mutations on the pump activity21–23.
The most susceptible isolates show major deletions in mexA or mexB leading to the production of truncated 
or aberrant proteins. Over the 8–512 mg/L range of MICs, mexA mutations are found in the regions encoding the 
α -helical hairpin and/or of the second, third, and membrane-proximal (MP) domains, which interact with MexB 
and/or OprM proteins24, possibly affecting the linkage with MexB or OprM, and therefore the correct assembly 
of the tripartite efflux system22. mexB mutations are located either in the regions building the pore domain (PC1, 
PC2, PN1, and PN2) implicated in drug recognition and extrusion25, or in those encoding the periplasmic tip of 
the docking subdomains (DN and DC) involved in the interaction with OprM25. Only one isolate (3319) showed 
an additional amino acid substitution outside these domains, namely in the cytoplasmic C-terminal domain 
of MexB25. Deletions in transmembrane helices TM8-12 were also identified in a few isolates. TM10 has been 
shown to mediate proton translocation (with the TM4) in the inner membrane domains26. Of interest, we noticed 
different mutations and hence, different susceptibility to temocillin, among clonal isolates, suggesting a high 
adaptability of each of them to its own environment.
Of note, most of the isolates also showed a high frequency of synonymous mutations and codon degeneracy 
especially at the third position. Most of these mutations were conserved among several isolates from different 
countries. Synonymous substitutions are often considered as silent mutations, but they can impact gene transcrip-
tion and mRNA transport or translation, which could alter protein folding and function27. Codon degeneracy is 
described as highly frequent in P. aeruginosa28.
Intriguingly, restoration of temocillin activity was only partial in some isolates that showed major deletions 
in mexA or mexB. Since we did not investigate the impact of each evidenced mutation on temocillin MIC in a 
PAO1 background, we cannot exclude that this is due to the expression of other, still undescribed mechanisms 
of resistance, or to an overexpression of other efflux systems that may compensate for the loss of MexAB-OprM 
activity, as previously described in CF isolates29. However, we previously showed that these systems only play a 
marginal role in temocillin extrusion6. Therefore, we suggest a possible phenotypic resistance related to an over-
production of extracellular polymeric substances, including alginate, in isolates with temocillin MICs ≥ 4 mg/L. 
Alginate has been shown to impair the diffusion, and therefore the activity, of ticarcillin, the parent compound 
of temocillin14,15. We show here that alginate production is systematically low in isolates with a temocillin MIC 
of 2 mg/L, i.e. a value corresponding to that measured for the mexAB deletion mutant of the non-mucoid refer-
ence PAO1, while it is high in clinical isolates with inactive efflux but temocillin MICs of 32–128 mg/L. Of note, 
we were able to exclude or minimize the role of two known mechanisms of resistance to β -lactams, namely the 
expression of β -lactamase(s) and reduced expression of porins. Thus, no β -lactamase among the few ones capable 
of hydrolysing temocillin (VIM, NDM, IMP, OXA-4830) was genotypically detected in our isolates. For porins, 
while OprD alterations have been previously evidenced in this collection31, we show here that, in contrast to 
carbapenems, temocillin does not require this porin to enter bacteria, but rather uses the anion-specific porins, 
OpdK and OpdF, the role of which seems redundant. Temocillin indeed shares a methoxy moiety with cefoxitine 
and vanillate, two well-established substrates of these porins. This moiety has been described for vanillate as 
interacting with the L3-L7 loops forming the internal constriction of OpdK18. Yet, the importance of these porins 
in temocillin uptake seems rather marginal since their inhibition increases temocillin MIC of 1 two-fold dilution 
only. For this reason, we did not specifically look for mutations or reduced expression of these porins in the col-
lection. We cannot exclude that other porins expressed by P. aeruginosa32 that were not investigated here also play 
a role in temocillin uptake. We acknowledge this is a limitation of this work.
Considering all data, and despite remaining uncertainty regarding the reason for variable susceptibility to 
temocillin in mutated isolates, our work brings three major pieces of scientific progress. Firstly, from a clinical 
perspective, we demonstrate a potential use for temocillin in the management of P. aeruginosa infections in CF 
patients. Although limited to a small proportion of isolates, this is important as temocillin susceptibility was 
observed for some isolates that were resistant to other β -lactams, either by production of β -lactamases or by 
alteration of the OprD porin, as well as in isolates belonging to clones described as multidrug-resistant. Thus our 
data call for introducing temocillin in routine susceptibility testing for P. aeruginosa collected from CF patients. 
Moreover, temocillin may offer the advantage of acting at the same time on Burkholderia spp5 that can co-infect 
CF patients.
Second, in a context of drug design, we observed a large diversity of mutations in mexA and mexB, opening 
perspectives for studying their role in substrate recognition and/or transport activity. The mutants described 
here could also be used to study the efflux of other antibiotics and to help delineating how these interact with 
specific domains of MexA and MexB. Third, from an ecological perspective, our data reinforce the concept that a 
functional MexAB-OprM pump is not needed for P. aeruginosa survival in the CF lung29 and illustrates the high 
adaptability of this bacteria to its environment.
Materials and Methods
P. aeruginosa isolates. A total of 333 isolates were randomly collected from 155 patients in four CF centres 
from different countries (Hôpital des enfants malades Reine Fabiola/Erasme; Belgium, n = 88; Hôpital Jean Minjoz, 
Besançon, France; n = 80; University Hospital of Münster, n = 66, Germany; Queen’s University of Belfast, UK, 
n = 99) during routine periodic visits (Table S1). PAO1, mutants thereof overexpressing or deleted for MexAB-
OprM (Table 1), and PA14 were used as control strains. The molecular typing of part of this collection has been 
previously performed by pulse field gel electrophoresis, focusing on isolates collected simultaneously from the 
same patients but differing in their susceptibility profile9. It was completed here for selected sequenced isolates 
following the same procedure.
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Antibiotics. The following antibiotics were obtained as microbiological standard from Sigma-Aldrich, St 
Louis, MO (sodium salts, potency in brackets): ticarcillin (TIC; 85.25%), piperacillin (PIP; 94.20%), carbenicil-
lin (CAR; 89.16%), and cefoxitin (FOX; potency, 95.11%). The remaining antibiotics were obtained as powder 
for parenteral use from their corresponding manufacturers (potency in brackets): temocillin (TMO, 78.12%) as 
Negaban® from Eumedica (Manage, Belgium), piperacillin-tazobactam (TZP; 97.00%) as Tazocin® from Wyeth 
(Louvain-La-Neuve, Belgium), ceftazidime (CAZ, 88.20%) as Glazidim® from Glaxo-SmithKline (Genval, 
Belgium), imipenem (IPM, 45.60% [due to the presence of cilastatin in the powder]) as Tienam® from MSD 
(Brussels, Belgium), and meropenem (MEM, 74.00%) as Meronem® from AstraZeneca (Brussels, Belgium).
Susceptibility testing. MICs were determined by broth microdilution following the guidelines from the 
Clinical and Laboratory Standards Institute and using P. aeruginosa ATCC27853 as a quality control. Susceptibility 
was assessed according to the interpretive criteria of the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) or using a cut-off value of 16 mg/L for temocillin (no EUCAST breakpoint) by analogy with 
the current susceptibility breakpoint of its parent compound ticarcillin. For specific isolates, MICs were also 
measured in the presence of 20 mg/L Phe-Arg-β -naphthylamide dihydrochloride (PAβ N, broad-spectrum efflux 
pump inhibitor10; Sigma-Aldrich) and of 1 mM MgSO4 (to prevent the outer membrane permeabilization caused 
by PAβ N33) or in the presence of substrates of P. aeruginosa porins, namely vanillate (VNL, OpdK substrate18), or 
L-arginine (L-Arg, OprD substrate19), both obtained from Sigma-Aldrich.
β-lactamases screening and identification. Isolates showing MICs > 8 mg/L for both ceftazidime and 
meropenem (n = 53) were screened for the presence of genes encoding acquired metallo-β -lactamases (VIM, 
IMP, NDM), carbapenemases (OXA-48, KPC), or widespread extended-spectrum β -lactamases (ESBLs) by PCR, 
as previously described9. The expression of carbapenemase(s) was also screened using a phenotypic method 
described as the Carbapenemase Nordmann-Poirel (Carba NP) test34.
Sequencing of mexA and mexB. mexA and mexB genes were amplified by PCR using the following 
primers: mexA-F (5′ -GCGAGGCTTTCGGACGTTTA-3′ ); mexA-R (5′ -GGCAGACTGAGGATCGACA-3′ ), 
mexB1-F (5′ -CAAGGGGATTCGTAATGTC-3′ ); mexB1-R (5′ -GTGAACATCCAGATCATCC-3′ ), mexB2-F  
(5′ -CGGATGTTCCTTTCCACCAC-3′ ); mexB2-R (5′ -GACAGAACGACAGCGGCTA-3′ ). Annealing temper-
atures for each pair of primers and amplicon sizes were as follows: mexA, 60 °C, 1375 bp; mexB1, 61 °C, 1684 bp; 
mexB2, 67 °C, 1638 bp. Sanger sequencing was performed in forward and reverse directions at GATC Biotech 
(Konstanz, Germany) using the same primers. PAO1 was used as a reference. Molecular graphics for MexA and 
MexB proteins were rendered using Visual Molecular Dynamics program (VMD35), based on Protein Data Bank 
(PDB) files 2V4D (MexA24), and 2V50 (MexB25).
Direct measurement of efflux activity. Efflux pump functionality was assayed by following the kinetics 
of efflux of N-phenyl-1-naphthylamine (NPN; Sigma-Aldrich), a MexAB-OprM preferential substrate11, which 
is fluorescent when incorporated in bacterial membranes. As previously described36, bacteria were treated with 
carbonyl cyanide m-chlorophenylhydrazone (CCCP, 10 μ M; Sigma-Aldrich) and then loaded with 20 μ M NPN. 
Efflux was initiated by energizing bacteria with 50 mM D-glucose (Sigma-Aldrich). Decay in fluorescence signal 
was followed over time using a Spectramax® multiplate reader (Molecular devices, Sunnyvale, CA). Maximal 
velocity (Vmax) was calculated by the SoftMax® Pro Microplate Data Acquisition and Analysis Software (version 
6.2). PAO1mexAB (Δ mexAB-mutant) was used as negative control.
Cloning and overexpression of porins. Genes encoding different porins i.e. OprD (OccD1), OpdK 
(OccK1), and OpdF (OccK2) were cloned in a heterologous system of Escherichia coli, which was lacking the 
main native porins OmpC and OmpF (E.coli K-12 W3110:Δ ompFΔ ompC)37. The genes opdK and opdF were 
PCR amplified from PAO1 (with HindIII and NsiI restriction site overhangs) and further cloned into pGOmpF 
(a vector with the signal sequence of phoE [phosphoporin protein E] attached to the ompF gene38) via HindIII/PstI, 
thereby replacing only ompF. This resulting vectors (pG-OpdK or pG-OpdF) had thus opdK and opdF attached to the 
phoE signal sequence and was further under the control of the lac promoter. The expression of opdK or opdF was induc-
ible by 0.5 mM IPTG. The pB22-OprD construct was a kind gift from Prof. Bert van den Berg, Newcastle, UK. In this 
E. coli expression vector, the oprD gene with the signal sequence of the E. coli outer membrane protein YtfM is under 
the control of the PBAD promoter inducible by 0.5% (w/v) arabinose. MICs were determined in the presence of inducer.
Single-porin P. aeruginosa mutants. Insertion mutants for the same 3 porins were obtained from the 
PA14 transposon insertion mutant library from the Harvard Medical School, Boston, MA39. This transposon 
library has been previously characterized and sequenced in order to identify insertion sites40; all transformants 
were resistant to gentamicin, confirming the expression of the gentamicin-resistance gene present on the inser-
tion cassette.
Quantification of extracellular polymeric saccharides (EPS). EPS were quantified using calcofluor 
white (BD™ Diagnostics, Sparks Glencoe, MD), a fluorophore which binds to β -(1, 4) and β -(1, 3) polysaccha-
rides41, including alginate (co-polymer of O-acetylated β -(1, 4) D-mannuronic acid and L-guluronic acid), a 
major constituent of slime produced by mucoid P. aeruginosa. Bacteria were cultured in 96-well plates as for MIC 
determinations (starting inoculum, 106 CFU/mL; 24 h incubation), after which bacterial density was evaluated by 
measuring OD620nm. The content of the wells was transferred to Eppendorf tubes and calcofluor white at a final 
concentration of 30 mg/L was added. The tubes were incubated for 30 minutes at room temperature and subse-
quently centrifuged at 20,800 g. Pellets were washed with phosphate buffered saline (PBS pH 7.4), resuspended 
in the same buffer, and transferred in black 96-well plates to measure fluorescence in a Spectramax® multiplate 
www.nature.com/scientificreports/
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reader (λ exc 370 nm; λ em 440 nm). Fluorescence values were normalized vs. the OD620nm of the cultures, with the 
value measured for PAO1 set to 1 as a reference.
Statistical analyses. Statistical analysis was performed using JMP® version 12.1.0, SAS Institute Inc., Cary, 
NC, USA or GraphPad Prism version 7.01 (GraphPad software Inc., San Diego, CA).
Ethics. The protocol for this study has been examined by the ethical committee of the Université catholique 
de Louvain, who determined that it did not fall under the scope of the law on human experimentation as (i) all 
isolates were collected during routine sampling and assembled retrospectively, and (ii) all patients’ data were 
anonymized.
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